HealthCare Global Enterprises Reports ₹5.58 Crore Q2 FY27 Profit

HealthCare Global Enterprises Limited reported a profit of ₹5.58 crore for the quarter ended September 30, 2026, its Q2 FY27 period. The company also disclosed total comprehensive income of ₹2.92 crore for the six months ended September 30 and total standalone assets of ₹2,925.60 crore at the period end.

What did HCG report for Q2 FY27?

HCG announced unaudited financial results for the quarter and six months ended September 30, 2026, reporting quarterly profit of ₹5.58 crore. The result disclosure was issued on November 5, 2026, the date previously indicated for the board meeting and Q2 FY27 results announcement.

For the six-month period, HCG reported total comprehensive income of ₹2.92 crore. Total comprehensive income can include items beyond the period's profit or loss, and the supplied disclosure does not provide a detailed reconciliation of the two figures. It also does not specify quarterly revenue, operating profit, or earnings per share for Q2 FY27.

The result announcement provides a reported profit figure but limited operating detail. Investors therefore have a confirmed Q2 profit number, while fuller information on revenue trends, margins, occupancy, patient volumes, and segment performance was not included in the supplied update.

What are the key figures in HCG's latest disclosure?

The main disclosed figures are Q2 FY27 profit of ₹5.58 crore, six-month total comprehensive income of ₹2.92 crore, and standalone total assets of ₹2,925.60 crore. All figures below have been converted to crore for consistency.

The asset figure is taken from the standalone balance sheet and represents the company's reported asset base at September 30. It should not be treated as a measure of revenue or profit for the quarter. The supplied update does not give corresponding balance-sheet comparisons for the previous year or the immediately preceding quarter.

For broader context, HCG had reported sales of ₹693.39 crore and net profit of ₹13.77 crore for the quarter ended June 2026. Sales were stated to be 13.34% higher year on year, while net profit was 189.89% higher than the ₹4.75 crore recorded in the June 2025 quarter. The Q2 update does not provide enough financial line items to make a like-for-like revenue or margin comparison with Q1 FY27.

When will HCG discuss the Q2 FY27 results?

HCG has scheduled an earnings conference call for November 6, 2026, at 12:30 pm IST to discuss its Q2 and H1 FY27 unaudited results. The call follows the November 5 board meeting and results disclosure.

The company had earlier communicated that results would be declared on November 5, with the conference call to take place the following day. The call gives shareholders and market participants an opportunity to hear management's discussion of the reported performance and ask questions about the business.

Management commentary may provide context that is not contained in the brief financial update, including operating conditions, spending plans, subsidiary performance, and the factors affecting profitability. However, no specific guidance or financial outlook was disclosed in the supplied call intimation.

How were HCG shares and operations positioned before the results?

HCG shares were quoted at ₹620.40 on November 4, 2026, up ₹8.80 or 1.43% for the session, according to the supplied market data. A separate intraday quote showed the stock at ₹623 on November 4. These prices preceded the November 5 results announcement and should not be read as a market reaction to the reported Q2 numbers.

HCG operates hospitals and medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. The company held its 28th annual general meeting on September 18, 2026, where shareholders adopted FY26 audited financial statements and reappointed directors Simrun Mehta and Akshay Tanna.

The group has also disclosed several subsidiary-related capital actions during 2026. In August, the board approved a ₹16 crore cash investment in HCG Rajkot Hospitals LLP for working capital and repayment of dues. HCG Rajkot operates a 147-bed cancer hospital in Gujarat and reported FY26 revenue of ₹60.67 crore, compared with ₹55.49 crore in FY25.

Why do the Q2 figures matter to HCG investors?

The Q2 FY27 result matters because it supplies an updated profit figure and a current standalone asset position following a period of investments and corporate actions across HCG's hospital network. The disclosed ₹5.58 crore quarterly profit should be assessed alongside the limited information currently available on Q2 revenue and operating costs.

The company has previously announced plans to invest up to ₹253.66 crore, including ₹98 crore for debt repayment at HCG NCHRI LLP and up to ₹155.66 crore to acquire an additional 34% stake in Vizag Hospital. Separately, its board approved a rights issue of up to ₹425 crore in February 2026, with final terms such as price, entitlement ratio, and timing to be determined by the Rights Issue Committee.

HCG Kenya, a step-down subsidiary, also increased its holding in AMIL to 50.10% through an acquisition for KES 42,150. These transactions show the company has been pursuing investments and ownership changes across its network, while the Q2 release provides only a narrow view of the financial effect of those actions.

Conclusion

HCG reported Q2 FY27 profit of ₹5.58 crore for the quarter ended September 30, 2026, alongside six-month total comprehensive income of ₹2.92 crore and standalone total assets of ₹2,925.60 crore. The update confirms the result date and key figures, but it does not disclose Q2 revenue, margins, or other operating metrics needed for a fuller period-on-period assessment.

The next disclosed event is HCG's earnings call at 12:30 pm IST on November 6, 2026. Investors will watch for management's explanation of the Q2 numbers, the status of investments in subsidiaries and hospitals, and any update on the planned rights issue or other capital-allocation decisions.